Proteon Therapeutics, Inc. (PRTO)

[fredman]

According to the December 13, 2016 conference call for Proteon Therapeutics PRTO the results of the study presented was "Top Line" data. The company expects to get additional data from the study over the coming weeks and this and other data is expected to be presented at a number of medical meetings in Q1 and Q2, 2017. The company was expecting a bigger effect in the study but the results were still promising. The company will continue to work closely with the FDA under fast track designation and will likely explore the opportunity of potential endpoint revision. The company expects to be in discussions with the FDA and will provide more specifics after the first of the year. The Patency-2 trial is expected to be completed by Q2 2018. The company has enough cash on hand until Q3 2018.

Source: http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-eventDetails&EventId=5245007

I am optimistic of the results of the study and the data looks promising.

Any number of catalysts including a potential buyout / merger rumor or a few positive press releases from the company, and PRTO could easily fill the gap to ~ $5.38, if that resistance is broken, upwards of $10.00+ is very likely.

Long PRTO

All In My Opinion

Do Your Own Due Diligence!